Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Lexaria Bioscience Corp. (LXRP)

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Appoints Strategic Advisor, Advances Tech Platform as Alternative to Smoking and Vaping

Posted on November 14, 2019 by MissionIR

Lexaria Bioscience is dedicated to providing healthful alternatives to drug-substance inhalation by providing an edible technology that works as effectively as smoking or vaping at getting substances into the bloodstream The company’s DehydraTECH platform has been licensed to multiple companies … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advances Development of Proprietary Drug-Delivery Platform

Posted on November 13, 2019 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, continues to progress the development and patenting of its DehydraTECH(TM) platform. An article discussing the company reads, “The DehydraTECH(TM) drug-delivery platform can be used to deliver substances in … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Drug-Delivery Platform May Ease Overdose Risk in Cannabis Edibles

Posted on November 6, 2019 by MissionIR

Edible cannabis products are absorbed slowly Consumers of cannabis edibles often mistake the delayed effect for insufficiency, leading to overdosing DehydraTECH drug-delivery platform speeds up absorption, reducing overdose risk Sometimes what is gained on the roundabouts is lost on the … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Names New Senior Advisor

Posted on November 5, 2019 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, this morning announced the appointment of Gregg Smith as a Senior Advisor for the company. Smith is the founder of Evolution VC Partners (www.EvolutionVCP.com), a New York-based “culture … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Proprietary Drug-Delivery System Featured in Peer-Reviewed Medical Journal

Posted on November 1, 2019 by MissionIR

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced that results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published in the peer-reviewed medical journal Advances in Therapy. … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Stock Jumps After FDA Announcement on Smokeless Tobacco Products

Posted on October 31, 2019 by MissionIR

LXRP stock jumped by 24 percent following the FDA’s announcement FDA recently granted the first-ever, modified-risk orders to eight smokeless tobacco products DehydraTECH technology enhances oral delivery of nicotine The recent climb in the stock price of Lexaria Bioscience Corp. … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Applauds FDA Forward-Looking Decision on Reduced Risk Tobacco Format

Posted on October 24, 2019 by MissionIR

Global innovator in drug delivery platforms Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that the Food and Drug Administration (“FDA”), for the first time ever, has authorized the marketing of oral nicotine products through the Modified Risk Tobacco Product … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Platform Offers Alternative to Traditional Inhalation

Posted on October 18, 2019 by MissionIR

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative DehydraTECH(TM) platform works to deliver chemical compounds to the bloodstream at speeds similar to inhalation methods, offering an alternative to smoking. An article discussing the company further reads, “Lexaria’s noncombustion-based, noninhalation-based delivery method … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP), MissionIRNewsBreaks | Leave a comment

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advances Innovation Research Through Agreement with Altria

Posted on October 10, 2019 by MissionIR

The program focuses on the pursuit of reduced risk oral nicotine products that make use of Lexaria’s patented DehydraTECH drug delivery platform DehydraTECH has been studied extensively and both human/animal trials confirm its ability to enhance active ingredient absorption in … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Inks its Largest Single-Hospital Sale of Revolutionary STREAMWAY(R) System

Posted on October 9, 2019 by MissionIR

POAI recently announced the sale of 10 FDA-approved, CE-marked STREAMWAY Systems STREAMWAY Systems are the first truly continuous, direct-to drain fluid-disposal solutions designed specifically for medical applications The announcement is another positive indication that POAI subsidiary Skyline Medical offers tremendous qualitative, … Continue reading →

Posted in Lexaria Bioscience Corp. (LXRP) | Leave a comment